Understanding China’s Huge Expansion of Health Insurance

Why It Matters

The findings show that enrollment spikes can mask substantial shifts in market composition, affecting the true level of health‑risk coverage and the sustainability of both public‑private schemes and private insurers.

Key Takeaways

• CCSMI enrollment reached over 300 million people by 2023
• Private‑insurance purchases fell 13.7 % after CCSMI rollout
• Coverage amounts in private plans dropped 13.6 % and premiums 4.6 %
• Crowd‑out offsets about 25 % of CCSMI’s enrollment growth
• Stronger special‑drug coverage in CCSMI amplifies private‑insurance substitution

Pulse Analysis

Expanding health‑insurance coverage in developing economies often relies on public‑private partnership (PPP) models that blend government oversight with private delivery. China, already boasting near‑universal basic coverage, introduced the City‑Customised Supplemental Medical Insurance (CCSMI) in 2020 to bridge gaps in out‑of‑pocket spending. By delegating sales and claims to private insurers while keeping premiums low—typically US$10‑25 per year—CCSMI quickly scaled, enrolling over 300 million citizens across more than 280 city‑level products by 2023. This design aims to mitigate adverse selection and lower per‑capita costs, positioning the scheme as a cost‑effective supplement to the existing tiered system.

Empirical analysis of a major insurer’s transaction data uncovers a pronounced crowd‑out effect. After CCSMI’s introduction, private‑insurance purchases declined 13.7 % (extensive margin), while remaining policyholders reduced coverage levels by 13.6 % and paid 4.6 % lower premiums (intensive margin). The net result is that roughly one‑quarter of the enrollment surge is offset by substitution toward the public‑backed supplement. Cities offering broader special‑drug coverage within CCSMI saw larger drops in private‑insurance uptake, indicating that benefit overlap drives consumer choice. These dynamics suggest that enrollment figures alone can overstate the expansion of genuine risk protection.

Policymakers should therefore treat PPP insurance growth as a nuanced metric. While low‑cost, unrestricted access can attract underserved groups, the associated crowd‑out may erode the more comprehensive protection offered by private products and pressure insurers’ pricing strategies. Designing PPP schemes with clear risk segmentation, coordinated benefit structures, and transparent consumer information can reduce direct substitution and preserve multi‑tier market balance. As other emerging economies consider similar models, understanding the trade‑off between rapid enrollment and effective risk coverage will be critical for sustainable health‑financing reforms.